Australia's Clarity Pharmaceuticals rises on PETNET Solutions agreement

Clarity Pharmaceuticals

14/06/2023 03:17

** Shares of Clarity Pharmaceuticals Ltd  CU6.AX  rise as
much as 5.1% to A$0.82, their highest level since April 24
    ** Clinical-stage radiopharmaceutical co enters master
service agreement and clinical supply agreement with PETNET
Solutions Inc    
    ** Co sees biggest intraday jump since May 29
    ** Under clinical supply agreement, PETNET Solutions will
manufacture ready-to-use Cu SAR-bisPSMA, an investigational
positron emission tomography (PET) agent, for co  
    ** PET agents are used for imaging purposes of the human
body 
    ** Says Cu SAR-bisPSMA is anticipated to enter Phase III
trial in the U.S. before the end of 2023 
    ** Shares of co on track for third day of consecutive gains 
    ** Stock down 21.2% YTD as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))